Advertisement

Article | 2026 AAO Meeting

Assessing PRIMA’s Efficacy and Safety at 36 Months

Long-term results from the PRIMAvera study show approximately 30 letters of mean visual acuity improvement at 36 months, with most serious adverse events occurring early after surgery.

By: Ehsan Rahimy, MD
Retinal Physician October 14, 2026
5 Key Takeaways

  • 1

    PRIMAvera enrolled 38 patients with advanced end-stage geographic atrophy across more than 17 European clinical sites.

  • 2

    Participants began with mean visual acuity equivalent to approximately 20/460 and gained a mean of 25 ETDRS letters at 12 months.

  • 3

    At 36 months, mean visual acuity improvement had increased to approximately 30 ETDRS letters.

  • 4

    The study reported 29 serious adverse events, and 83% occurred within 6 months after surgery.

  • 5

    Serious adverse events were managed without compromising natural vision, and nearly two-thirds of affected patients gained at least 15 ETDRS letters.